Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis-Reference-Cited by-同舟云学术

Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis

Published:2015-08 Issue:2 Volume:68 Page:317-324
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Brasso Klaus,Thomsen Frederik B.,Schrader Andres J.,Schmid Sebastian C.,Lorente David,Retz Margitta,Merseburger Axel S.,von Klot Christoph A.,Boegemann Martin,de Bono Johann

Publisher

Elsevier BV

Subject

Urology

Reference24 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;De Bono;Lancet,2010

4. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

5. Abiraterone and increased survival in metastatic prostate cancer;De Bono;N Engl J Med,2011

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial;European Journal of Cancer;2024-07

2. Nanotherapeutics for prostate cancer treatment: A comprehensive review;Biomaterials;2024-03

3. Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire;Biomedicines;2023-07-24

4. Proxalutamide in metastatic castration‐resistant prostate cancer: Primary analysis of a multicenter, randomized, open‐label, phase 2 trial;International Journal of Cancer;2023-04-10

5. Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells;Molecular Cancer Therapeutics;2023-01-11